Konstantinos Angelis
Title
Cited by
Cited by
Year
Uncertainty in the timing of origin of animals and the limits of precision in molecular timescales
M Dos Reis, Y Thawornwattana, K Angelis, MJ Telford, PCJ Donoghue, ...
Current Biology 25 (22), 2939-2950, 2015
2082015
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 …
JM Llibre, CC Hung, C Brinson, F Castelli, PM Girard, LP Kahl, EA Blair, ...
The Lancet 391 (10123), 839-849, 2018
1842018
Global dispersal pattern of HIV type 1 subtype CRF01_AE: a genetic trace of human mobility related to heterosexual sexual activities centralized in Southeast Asia
K Angelis, J Albert, I Mamais, G Magiorkinis, A Hatzakis, O Hamouda, ...
The Journal of infectious diseases 211 (11), 1735-1744, 2015
422015
The global spread of HIV-1 subtype B epidemic
G Magiorkinis, K Angelis, I Mamais, A Katzourakis, A Hatzakis, J Albert, ...
Infection, genetics and evolution 46, 169-179, 2016
412016
The impact of ancestral population size and incomplete lineage sorting on Bayesian estimation of species divergence times
K Angelis, M Dos Reis
Current Zoology 61 (5), 874-885, 2015
372015
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health
GA McComsey, S Lupo, D Parks, MC Poggio, J De Wet, LP Kahl, ...
AIDS (London, England) 32 (4), 477, 2018
272018
Safety and efficacy of dolutegravir-based ART in TB/HIV coinfected adults at week 24
K Dooley, R Kaplan, N Mwelase, B Grinsztejn, E Ticona, M Lacerda, ...
25th Conference on Retroviruses and Opportunistic Infections (CROI), 2018
222018
Dating the origin of hepatitis B virus reveals higher substitution rate and adaptation on the branch leading to F/H genotypes
D Paraskevis, K Angelis, G Magiorkinis, E Kostaki, SYW Ho, A Hatzakis
Molecular phylogenetics and evolution 93, 44-54, 2015
212015
An evaluation of different partitioning strategies for Bayesian estimation of species divergence times
K Angelis, S Álvarez-Carretero, M Dos Reis, Z Yang
Systematic biology 67 (1), 61-77, 2018
202018
Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 …
M Aboud, C Orkin, D Podzamczer, JR Bogner, D Baker, ...
The Lancet HIV 6 (9), e576-e587, 2019
152019
Bayesian estimation of nonsynonymous/synonymous rate ratios for pairwise sequence comparisons
K Angelis, M dos Reis, Z Yang
Molecular Biology and Evolution 31 (7), 1902-1913, 2014
152014
Unravelling the history of hepatitis B virus genotypes A and D infection using a full-genome phylogenetic and phylogeographic approach
EG Kostaki, T Karamitros, G Stefanou, I Mamais, K Angelis, A Hatzakis, ...
Elife 7, e36709, 2018
112018
Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial
KE Dooley, R Kaplan, N Mwelase, B Grinsztejn, E Ticona, M Lacerda, ...
Oxford University Press, 2019
102019
Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial
KE Dooley, R Kaplan, N Mwelase, B Grinsztejn, E Ticona, M Lacerda, ...
Clinical Infectious Diseases 70 (4), 549-556, 2020
72020
The impact of Measles-Rubella vaccination on the morbidity and mortality from Congenital Rubella Syndrome in 92 countries
E Vynnycky, P Timoleon, K Angelis
Human Vaccines & Immunotherapeutics 15 (2), 309-316, 2018
62018
Durable suppression and low rate of virologic failures 3 years after switch to DTG+ RPV 2DRug Regimen: SWORD 1 and 2 Studies
J van Wyk, C Orkin, R Rubio, J Bogner, D Baker, MA Khuong-Josses, ...
25th Annual Conference of the British HIV Association, 2-5, 2019
52019
Renal, inflammatory and bone biomarkers following switch to the DTG+ RPV 2-drug regimen: the SWORD-1 & SWORD-2 studies
C Orkin, JM Llibre, L Kahl, E Blair, B Wynne, L Curtis, K Angelis, R Shah, ...
16th European AIDS Conference, 25-27, 2017
52017
Comparison of viral replication below 50 copies/mL for two-drug (DTG plus RPV) versus three-drug current antiretroviral regimen (CAR) therapy in the SWORD-1 and SWORD-2 studies
M Underwood, K Angelis, R Wang, B Wynne, E Blair, L Kahl, T Vincent, ...
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21, 2018
32018
Patient reported outcomes after switching to a 2 drug regimen of dolutegravir+ rilpivirine: results from the SWORD-1 and SWORD-2 studies
A Oglesby, AS Punekar, K Angelis, A Antela, M Aboud, E Blair, L Kahl, ...
16th European AIDS conference, 25-27, 2017
22017
Safety and efficacy of DTG+ RPV in the phase III SWORD-1 and SWORD-2 studies: 48-week subgroup analysis by baseline third agent class and geographic location [abstract no. P22]
C Orkin, MA Khuong-Josses, T Lutz, D Baker, R Rubio, E Blair, L Kahl, ...
HIV Med 19 (Suppl 2), S28-9, 2018
12018
The system can't perform the operation now. Try again later.
Articles 1–20